Estrella Immunopharma (ESLA) Other Non-Current Liabilities (2023 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Other Non-Current Liabilities of $465132.0 for Q1 2026, up 30.47% quarter-over-quarter from $356505.0 in Q4 2025.
Estrella Immunopharma (ESLA) Other Non-Current Liabilities (2023 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Other Non-Current Liabilities for 4 consecutive years, with $465132.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities changed N/A year-over-year to $465132.0; the TTM figure through Mar 2026 stood at $465132.0 (changed N/A YoY), while the FY2025 annual figure was $356505.0, up 12.0% from the prior year.
- Other Non-Current Liabilities rose to $465132.0 in Q1 2026 per ESLA's latest filing, from $356505.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $465132.0 in Q1 2026 and bottomed at $12725.0 in Q2 2023.
- Historically, Other Non-Current Liabilities has averaged $287662.3 across 4 years, with a median of $337410.5 in 2024.
- On a YoY basis, Other Non-Current Liabilities climbed as much as 12.0% in 2025 and fell as far as 12.0% in 2025.
- Estrella Immunopharma's Other Non-Current Liabilities stood at $12725.0 in 2023, then surged by 2401.5% to $318316.0 in 2024, then gained by 12.0% to $356505.0 in 2025, then jumped by 30.47% to $465132.0 in 2026.
- Business Quant data shows ESLA's Other Non-Current Liabilities at $465132.0 in Q1 2026, $356505.0 in Q4 2025, and $385355.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Estrella Immunopharma | 32.29 Mn | 32.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 687,224.00 |
| Mar 31, 2026 | 465,132.00 |
| Dec 31, 2025 | 356,505.00 |
| Sep 30, 2025 | 385,355.00 |
| Jun 30, 2025 | 187,941.00 |
| Dec 31, 2024 | 318,316.00 |
| Jun 30, 2023 | 12,725.00 |